



**MESAS SPR**

---

L

## Mesas SPR

ACTA REUMATOL PORT. 2016;31:53-54 (SUP)

### MESA SPR – CELGENE

#### APREMILAST: UMA NOVA TERAPÊUTICA ORAL NA ARTRITE PSORIÁTICA

Christopher J Edwards

University Hospital Southampton NHS Foundation Trust

MODERADOR: Elsa Vieira de Sousa

Nesta Sessão serão apresentados os resultados dos estudos clínicos com Apremilast na Artrite Psoriática e discutidas possíveis implicações na prática clínica corrente.

### MESA SPR – PFIZER

#### SIGNALING THE FUTURE IN RA MANAGEMENT

MODERADOR: Joaquim Polido Pereira

#### JAK PATHWAY: TARGETING INTRACELLULAR SIGNALING

John Isaacs

Institute of Cellular Medicine at Newcastle University

#### JAK PATHWAY: CLINICAL TRIAL PROGRAMME

Maria José Santos

Serviço de Reumatologia - Hospital Garcia de Orta, EPE

A via de sinalização JAK-STAT desempenha um papel importante na inflamação sinovial da Artrite Reumatóide. A modulação desta via pode fornecer uma estratégia terapêutica eficaz no tratamento dos doentes com Artrite Reumatóide.

### MESA SPR – ABBVIE

#### THE COMPLEXITY OF SPONDYLOARTHRITIS (SPA) AND HOW TO APPROACH FEATURES OF SPA IN DAILY PRACTICE

Pedro Machado

University College London

MODERADOR: José Canas da Silva

Spondyloarthritis (SpA) is a complex and chronic inflammatory disease with diverse phenotypic manifestations and frequent comorbidities. The overlapping immunopathology indicates that the different phenotypic manifestations share common pathogenic pathways. Data from pre-clinical and clinical studies suggest a pivotal role for TNF $\alpha$  in the immunopathology of SpA.

How to approach clinical features of SpA, including extra-articular manifestations, like uveitis, inflammatory bowel disease and psoriasis is a challenge that should be addressed in daily clinical practice. Understand the appropriate therapeutic targets and treat all aspects of the disease, using a drug or combination of drugs which fits the individual profile of the patient, aiming for simplicity, should also be addressed.

The ultimate objective is to attain the absence of inflammation and improve the patient's quality of life, always aiming for a standardized quality of care in SpA rheumatology clinical practice.

### MESA SPR - ROCHE

#### FINDING THE BEST FIT: THERAPEUTIC OPTIONS FOR PATIENTS WITH RA

MODERADOR: José Canas da Silva

#### REAL WORLD DATA AS THE EVIDENCE

Maria José Santos

Serviço de Reumatologia – Hospital Garcia de Orta, EPE

#### CLINICAL TRIALS AS THE EVIDENCE

Gerolamo Bianchi

Reumatologia Ospedale La Colletta

The major goals in this "question and answer" model is to review available data, including randomized controlled trial (RCT) and real world data (RWD) as a support to therapeutic decisions in rheumatoid arthritis.